| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9ae079092f2e6b17a5c5110af960b6c4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2821
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4711
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-16 |
| filingDate |
2016-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_216bfc2695688d01118cc8e1526bfdfd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0cf8d4f7225d3f55bd5eac1661e73e23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a1430075da099065750a087544e2011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4fbc23a9db1b91bc26f4ea9ef5b94d5 |
| publicationDate |
2016-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2016189163-A1 |
| titleOfInvention |
Biomolecules involved in alzheimer's disease |
| abstract |
The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and/or 2',3'-cyclic-nucleotide 3'-phosphodiesterase and/or phosphorylated tau or fragments thereof and methods using thereof for diagnosing, staging, treating and assessing the response of a treatment for a neurocognitive disorder characterised by tau toxicity, in particular for Alzheimer's disease. The present invention shows that the biomarkers disclosed herein are elevated in the brain of subjects with an advanced stage of a neurocognitive disorder (Braak stage V/VI) and/or are regulated in the CSF of AD subjects in comparison to cognitively affected non-AD controls; and/or regulated in response to two casein kinase 1 delta inhibitors. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GR-20170100034-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110261619-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110261619-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3810156-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019009985-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11493513-B2 |
| priorityDate |
2015-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |